![]() |
市場調查報告書
大型製藥公司預測Big Pharma Outlook 2026 |
||||||
出版商 | Datamonitor Healthcare | 商品編碼 | 342057 | ||||
出版日期 | 內容資訊 | 英文 70 Pages 商品交期: 最快1-2個工作天內 |
|||||
價格 |
|
大型製藥公司預測 Big Pharma Outlook 2026 | ||
出版日期: 2017年07月13日 | 內容資訊: 英文 70 Pages |
|
大型製藥公司,由於有強力的開發組合、高潛在能力的開發平台資產、尖銳性的高成長市場,預計將成長。
本報告提供大型製藥公司預測調查分析、策略的推動因素、收益趨勢、治療領域等系統性資訊。
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2026. A healthy launch portfolio will bolster growth as Big Pharma reaps the reward of breakthrough products as the result of recent industry innovation. By delving deeper into revenue trends, therapy area performance, and strategic drivers, this analysis is vital to understanding how Big Pharma will navigate headwinds in order to steer towards robust growth.